JANX 008
Alternative Names: EGFR TRACTr - Janux Therapeutics/Merck & Co; EGFR-TRACTr; Epidermal growth factor receptor tumour activated T-cell engager therapy - Janux Therapeutics/Merck & Co; JANX-008Latest Information Update: 28 Feb 2024
At a glance
- Originator Janux Therapeutics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Peptides; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Feb 2024 Efficacy and adverse events data from a phase Ia trial in Solid tumours released by Janux Therapeutics
- 14 Mar 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in USA (IV) (NCT05783622)
- 10 Mar 2023 US FDA approves IND application for JANX 008 in Solid tumors as of March 2023